Gene therapy for bladder control: 5-year safety watch begins

NCT ID NCT07227285

Not yet recruiting Knowledge-focused Sponsor: EG 427 Source: ClinicalTrials.gov ↗

First seen Nov 12, 2025 · Last updated May 09, 2026 · Updated 21 times

Summary

This study follows 16 people who already received EG110A, a gene therapy for overactive bladder caused by spinal cord injury. Researchers will track side effects and how well the treatment works over five years. The goal is to understand long-term safety and dosing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL CORD INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Rancho Los Amigos National Rehabilitation Center

    Downey, California, 90242, United States

    Contact

  • Sidney Kimmel Medical College

    Philadelphia, Pennsylvania, 19107, United States

    Contact

  • UTHealth Houston / TIRR Memorial Hermann

    Houston, Texas, 77030, United States

    Contact

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

    Contact

Conditions

Explore the condition pages connected to this study.